)
HYDERABAD: Biological E’s Covid-19 vaccine, Corbevax, is likely to get an emergency-use authorisation (EUA) for use in children in the 5-12 years age bracket following recommendations from the subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) to the drug regulator.
According to sources, the SEC has taken the decision to recommend EUA for India’s first indigenously developed recombinant protein-subunit vaccine for 5- to 12-year olds to the Drugs Controller General of India (DCGI), at its meeting held on Thursday.
However, the vaccine will first need to get approval for emergency use from the DCGI before it can be administered to children.
The SEC recommendation comes even as Covid-19 cases have been on the rise in several cities and schools are reopening, leaving kids vulnerable.
Corbevax is currently the only vaccine approved to be administered to children in the 12-14 years age group, while Bharat Biotech’s Covaxin is the only one to have been approved for use in children in the 15-18 years age group.
Biological E has developed the SARS-CoV-2 receptor binding domain (RBD) protein-subunit vaccine in partnership with Texas Children’s Hospital Centre for Vaccine Development, Baylor College of Medicine, at Houston.
According to sources, the SEC has taken the decision to recommend EUA for India’s first indigenously developed recombinant protein-subunit vaccine for 5- to 12-year olds to the Drugs Controller General of India (DCGI), at its meeting held on Thursday.
However, the vaccine will first need to get approval for emergency use from the DCGI before it can be administered to children.
The SEC recommendation comes even as Covid-19 cases have been on the rise in several cities and schools are reopening, leaving kids vulnerable.
Corbevax is currently the only vaccine approved to be administered to children in the 12-14 years age group, while Bharat Biotech’s Covaxin is the only one to have been approved for use in children in the 15-18 years age group.
Biological E has developed the SARS-CoV-2 receptor binding domain (RBD) protein-subunit vaccine in partnership with Texas Children’s Hospital Centre for Vaccine Development, Baylor College of Medicine, at Houston.
!function(f,b,e,v,n,t,s) {if(f.fbq)return;n=f.fbq=function(){n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}; if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version=’2.0′; n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0]; s.parentNode.insertBefore(t,s)}(window, document,’script’, ‘https://connect.facebook.net/en_US/fbevents.js’); fbq(‘init’, ‘593671331875494’); fbq(‘track’, ‘PageView’);
More News
Bombay HC upholds renaming of Aurangabad and Osmanabad, says no illegality by state | India News – Times of India
Haryana Govt Crisis: Haryana CM Nayab Saini Denies Trouble As 3 MLAs Withdraw Support Plunging BJP To Minority | Top Developents
What deal did Rahul Gandhi crack with Ambani, Adani that he stopped abusing them overnight: PM Modi at Telangana rally | India News – Times of India